The therapeutic potential of targeting ABC transporters to combat multi-drug resistance

References

• Tiwari KA, Sodani K, Dai C-L, et al. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 2011;12(4):570–594.
   PubMed Web of Science ®Google Scholar
• Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013;13(3):326–346.
   PubMed Web of Science ®Google Scholar
• Chen Z, Shi T, Zhang L, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 2016;370(1):153–164.
   PubMed Web of Science ®Google Scholar
• Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 2010;46(3):308–316.
   PubMed Web of Science ®Google Scholar
• Volm MAM. Oncogenesis. J Crit Rev. 1996;7:227–244.
   Google Scholar
• Dietel M. What’s new in cytostatic drug resistance and pathology. Pathology-Research Pract. 1991;187(7):892–905.
   PubMed Web of Science ®Google Scholar
• Beck WT. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev. 1990;17:11–20.
   PubMed Web of Science ®Google Scholar
• Morrow C, Cowan K. Glutathione S-transferases and drug resistance. Cancer Cells (Cold Spring Harbor, NY: 1989). 1990;2(1):15–22.
   PubMed Web of Science ®Google Scholar
• Hammond JR, Johnstone RM, Gros P. Enhanced efflux of [3H] vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the mdr1 gene. Cancer Res. 1989;49(14):3867–3871.
   PubMed Web of Science ®Google Scholar
• Liu Y, Han TY, Giuliano AE, et al. Ceramide glycosylation potentiates cellular multidrug resistance. Faseb J. 2001;15(3):719–730.
   PubMed Web of Science ®Google Scholar
• Fukuda Y, Schuetz JD. ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012;83(8):1073–1083.
   PubMed Web of Science ®Google Scholar
• Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer. Biochimica Et Biophysica Acta (Bba)-Reviews on Cancer. 1996;1288(2):F37–F54.
   Google Scholar
• Danø K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochimica Et Biophysica Acta (Bba)-Biomembranes. 1973;323(3):466–483.
   PubMed Web of Science ®Google Scholar
• Fletcher JI, Haber M, Henderson MJ, et al. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010;10(2):147–156. .
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst. 2000;92(20):1651–1656.
   PubMed Web of Science ®Google Scholar
• Leggas M, Adachi M, Scheffer GL, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol. 2004;24(17):7612–7621.
   PubMed Web of Science ®Google Scholar
• Paulusma CC, Bosma PJ, Zaman GJR, et al. Congenital jaundice in rats with mutation in a multidrug resistance–associated protein gene. Science. 1996;271(5252):1126.
   PubMed Web of Science ®Google Scholar
• Rao, V.V., Dahlheimer, J.L., Bardgett, M.E., et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood–cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci. 1999;96(7):3900–3905.
   PubMed Web of Science ®Google Scholar
• Schinkel A, Smit JJ, Van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491–502.
   PubMed Web of Science ®Google Scholar
• Linton K, Holland I. The ABC transporters of human physiology and disease. Singapore: World Scientific; 2011.
   Google Scholar
• Dean M. The genetics of ATP-binding cassette transporters. Methods Enzymol. 2005;400:409–429.
   PubMed Web of Science ®Google Scholar
• Kim S, Saito Y, Maekawa K, et al. Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab Pharmacokinet. 2006;21(3):248–256.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica Et Biophysica Acta (Bba)-Biomembranes. 1976;455(1):152–162.
   PubMed Web of Science ®Google Scholar
• Roninson, I.B., H.T. Abelson, D.E. Housman, N. Howell, and A. Varshavsky, Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells. Nature, 1984. 309: 626–628.
   Google Scholar
• Riordan, J.R., K. Deuchars, N. Kartner, N. Alon, J. Trent, and V. Ling, Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature, 1985. 316(6031):817–819.
   Google Scholar
• Loo TW, Bartlett MC, Clarke DM. Human P-glycoprotein contains a greasy ball-and-socket joint at the second transmission interface. J Biol Chem. 2013;288(28):20326–20333.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3–29.
   PubMed Web of Science ®Google Scholar
• Slot AJ, Molinski SV, Cole SP. Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011;50:179–207.
   PubMed Web of Science ®Google Scholar
• Zhang YK, Wang Y-J, Gupta P, et al. Multidrug resistance proteins (MRPs) and cancer therapy. Aaps J. 2015;17(4):802–812.
   PubMed Web of Science ®Google Scholar
• Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 2002;34(1–2):47–54.
   PubMed Web of Science ®Google Scholar
• Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol. 2006;25(4):231–259.
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92(16):1295–1302.
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Hoffmann U, Kroemer HK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol. 2006;2(3):351–366.
   PubMed Web of Science ®Google Scholar
• Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 2007;453(5):643–659.
   PubMed Web of Science ®Google Scholar
• Nies AT, Schwab M, Keppler D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol. 2008;4(5):545–568.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Wang -L-L, Di YM, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem. 2008;15(20):1981–2039.
   PubMed Web of Science ®Google Scholar
• Van Zanden JJ, Wortelboer HM, Bijlsma S, et al. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol. 2005;69(4):699–708.
   PubMed Web of Science ®Google Scholar
• Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem. 2011;50:161–178. .
   PubMed Web of Science ®Google Scholar
• Zolnerciks JK, Andress EJ, Nicolaou M, et al. Structure of ABC transporters. Essays Biochem. 2011;50:43–61.
   PubMed Web of Science ®Google Scholar
• Holland IB, Blight MA. ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J Mol Biol. 1999;293(2):381–399.
   PubMed Web of Science ®Google Scholar
• Jones PM, George AM. Mechanism of the ABC transporter ATPase domains: catalytic models and the biochemical and biophysical record. Crit Rev Biochem Mol Biol. 2013;48(1):39–50.
   PubMed Web of Science ®Google Scholar
• George AM, Jones PM. Perspectives on the structure–function of ABC transporters: the Switch and Constant Contact Models. Prog Biophys Mol Biol. 2012;109(3):95–107.
   PubMed Web of Science ®Google Scholar
• Qu Q, Sharom FJ. Proximity of bound Hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmic membrane leaflet. Biochemistry. 2002;41(14):4744–4752.
   PubMed Web of Science ®Google Scholar
• Lugo MR, Sharom FJ. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry. 2005;44(2):643–655.
   PubMed Web of Science ®Google Scholar
• Lugo MR, Sharom FJ. Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. Biochemistry. 2005;44(42):14020–14029.
   PubMed Web of Science ®Google Scholar
• Lugo MR, Sharom FJ. Interaction of LDS-751 with the drug-binding site of P-glycoprotein: a Trp fluorescence steady-state and lifetime study. Arch Biochem Biophys. 2009;492(1):17–28.
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. Mutational analysis of ABC proteins. Arch Biochem Biophys. 2008;476(1):51–64.
   PubMed Web of Science ®Google Scholar
• Jin MS, Oldham ML, Zhang Q, et al. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature. 2012;490(7421):566–569.
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. Drug rescue distinguishes between different structural models of human P-glycoprotein. Biochemistry. 2013;52(41):7167–7169.
   PubMed Web of Science ®Google Scholar
• Matheny CJ, Lamb MW, Brouwer KLR, et al. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy: J Hum Pharmacol Drug Ther. 2001;21(7):778–796.
   Web of Science ®Google Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105–127.
   PubMed Web of Science ®Google Scholar
• Zhou S-F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38(7–8):802–832.
   PubMed Web of Science ®Google Scholar
• Morrissey K, Wen CC, Johns SJ, et al. The UCSF‐FDA TransPortal: a public drug transporter database. Clin Pharmacol Ther. 2012;92(5):545–546.
   PubMed Web of Science ®Google Scholar
• Kathawala RJ, Gupta P, Ashby CR, et al. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat. 2015;18:1–17.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP–dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.
   PubMed Web of Science ®Google Scholar
• Findling-Kagan S, Sivan H, Ostrovsky O, et al. Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1. Leuk Res. 2005;29(4):407–414.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen H, Miller DS, et al. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol. 2001;60(2):302–309.
   PubMed Web of Science ®Google Scholar
• Sauna ZE, Smith MM, Müller M, et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr. 2001;33(6):481–491.
   PubMed Web of Science ®Google Scholar
• Peng -X-X, Tiwari AK, Wu H-C, et al. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chin J Cancer. 2012;31(2):110–118.
   PubMed Web of Science ®Google Scholar
• Marchetti S, De Vries NA, Buckle T, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/−(triple-knockout) and wild-type mice. Mol Cancer Ther. 2008;7(8):2280–2287.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci. 1997;94(8):4028–4033.
   PubMed Web of Science ®Google Scholar
• Alvarez M, Paull K, Monks A, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Investig. 1995;95(5):2205–2214.
   PubMed Web of Science ®Google Scholar
• Schöndorf T., Kurbacher CM, Göhring UJ, et al. Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res. 2001;22(4):2199–2203.
   Web of Science ®Google Scholar
• Schöndorf T, Scharl A, Kurbacher CM, et al. Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas. Cancer Lett. 1999;146(2):195–199.
   PubMed Web of Science ®Google Scholar
• Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein-and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol. 1997;53(4):461–470.
   PubMed Web of Science ®Google Scholar
• Xu X, Leo C, Jang Y, et al. Dominant effector genetics in mammalian cells. Nat Genet. 2001;27(1):23–29.
   PubMed Web of Science ®Google Scholar
• Choi K, Chen CJ, Kriegler M, et al. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell. 1988;53(4):519–529.
   PubMed Web of Science ®Google Scholar
• Devine SE, Ling V, Melera PW. Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. Proc Natl Acad Sci. 1992;89(10):4564–4568.
   PubMed Web of Science ®Google Scholar
• Gros P, Dhir R, Croop J, et al. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc Natl Acad Sci. 1991;88(16):7289–7293.
   PubMed Web of Science ®Google Scholar
• Mickley LA, Spengler BA, Knutsen TA, et al. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Investig. 1997;99(8):1947–1957.
   PubMed Web of Science ®Google Scholar
• Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Multi-Drug Resis Cancer. 2010;596:341–358.
   Google Scholar
• Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol. 2000;12(5):450–458.
   PubMed Web of Science ®Google Scholar
• Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. The Oncologist. 2003;8(5):411–424.
   PubMed Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219–234.
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Hamada H, Sato S, et al. Inhibition of multidrug resistant human tumor growth in athymic mice by anti p-glycoprotein monoclonal antibodies. Jpn J Cancer Res. 1989;80(7):627–631.
   PubMedGoogle Scholar
• Köhler S, Stein WD. Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles. Biotechnol Bioeng. 2003;81(5):507–517.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Cunnion RE, Klecker RW, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987;5(4):641–647.
   PubMed Web of Science ®Google Scholar
• Chan HS, DeBoer G, Thiessen JJ, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res. 1996;2(9):1499–1508.
   PubMed Web of Science ®Google Scholar
• List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98(12):3212–3220.
   PubMed Web of Science ®Google Scholar
• Li G-Y, Liu J-Z, Zhang B, et al. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia. Biomed Pharmacother. 2009;63(8):566–570.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Suciu S, Weijermans P, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914). Br J Haematol. 2001;115(4):895–902.
   PubMed Web of Science ®Google Scholar
• Warner E, Tobe SW, Andrulis IL, et al. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am J Clin Oncol. 1995;18(3):251–256.
   PubMed Web of Science ®Google Scholar
• Weber D, Dimopoulos M, Sinicrope F, et al. VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1995;19(1–2):159–163.
   PubMed Web of Science ®Google Scholar
• Darby AJ, Callaghan R,R, McMahon RM. P-glycoprotein inhibition: the past, the present and the future. Curr Drug Metab. 2011;12(8):722–731.
   PubMed Web of Science ®Google Scholar
• Ries F, Dicato M. Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continuous infusion of verapamil. A phase I-II clinical trial. Med Oncol Tumor Pharmacother. 1991;8(1):39–43.
   PubMedGoogle Scholar
• Yahanda AM, Alder KM, Fisher GA, et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1992;10(10):1624–1634.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schoester M, De Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol. 1994;12(8):1584–1591.
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Giglioni B, et al. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006;7(7):861–879.
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Mazzei T, et al. Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression. Med Res Rev. 2012;32(6):1220–1262.
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Vasconcelos MH, et al. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012;19(13):1946–2025.
   PubMed Web of Science ®Google Scholar
• Shaffer BC, Gillet J-P, Patel C, et al. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat. 2012;15(1):62–69.
   PubMed Web of Science ®Google Scholar
• Chico I, Kang MH, Bergan R, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol. 2001;19(3):832–842.
   PubMed Web of Science ®Google Scholar
• Lum BL, Gosland MP. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am. 1995;9(2):319–336.
   PubMed Web of Science ®Google Scholar
• Minderman H, O’Loughlin KL, Pendyala L, et al. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res. 2004;10(5):1826–1834.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Harding MW, Neubauer M, et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer. 2007;109(5):924–932.
   PubMed Web of Science ®Google Scholar
• Saeki T, Nomizu T, Toi M, et al. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J Clin Oncol. 2007;25(4):411–417.
   PubMed Web of Science ®Google Scholar
• Hyafil F, Vergely C, Du Vignaud P, et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993;53(19):4595–4602.
   PubMed Web of Science ®Google Scholar
• Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Cont. 2003;10(2):159–159.
   PubMedGoogle Scholar
• Dantzig A, Shepard RL, Law KL, et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther. 1999;290(2):854–862.
   PubMed Web of Science ®Google Scholar
• Fracasso PM, Goldstein LJ, De Alwis DP, et al. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res. 2004;10(21):7220–7228.
   PubMed Web of Science ®Google Scholar
• Martin C, Berridge G, Mistry P, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol. 1999;128(2):403–411.
   PubMed Web of Science ®Google Scholar
• Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001;61(2):749–758.
   PubMed Web of Science ®Google Scholar
• Kruijtzer CM, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol. 2002;20(13):2943–2950.
   PubMed Web of Science ®Google Scholar
• Kuppens IE, Witteveen EO, Jewell RC, et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res. 2007;13(11):3276–3285.
   PubMed Web of Science ®Google Scholar
• Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996;56(18):4171–4179.
   PubMed Web of Science ®Google Scholar
• Gerrard G, Payne E, Baker RJ, et al. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica. 2004;89(7):782–790.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Zinzani PL, Burgess M, et al. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2007;48(4):708–715.
   PubMed Web of Science ®Google Scholar
• Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010;116(20):4077–4085.
   PubMed Web of Science ®Google Scholar
• Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001;61(2):749–758.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005;104(4):682–691.
   PubMed Web of Science ®Google Scholar
• Kadioglu O, Saeed MEM, Valoti M, et al. Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: functional and molecular docking analyses. Biochem Pharmacol. 2016;104:42–51.
   PubMed Web of Science ®Google Scholar
• Cole S, Bhardwaj G, Gerlach J, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science-New York Then Washington-. 1992;258:1650–1650.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4:e532.
   PubMed Web of Science ®Google Scholar
• Sodani K, Patel A, Kathawala RJ, et al. Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer. 2012;31(2):58.
   PubMed Web of Science ®Google Scholar
• Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994;54(22):5902–5910.
   PubMed Web of Science ®Google Scholar
• Ishikawa T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci. 1992;17(11):463–468.
   PubMed Web of Science ®Google Scholar
• Brevig T, Krühne U, Kahn RA, et al. Hydrodynamic guiding for addressing subsets of immobilized cells and molecules in microfluidic systems. BMC Biotechnol. 2003;3(1):1.
   PubMed Web of Science ®Google Scholar
• Sun Y-L, Patel A, Kumar P, et al. Role of ABC transporters in cancer chemotherapy. Chin J Cancer. 2012;31(2):51.
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Wang -L-L, Di YM, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem. 2008;15(20):1981–2039.
   PubMed Web of Science ®Google Scholar
• Jemnitz K, Heredi-Szabo K, Janossy J, et al. ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metab Rev. 2010;42(3):402–436.
   PubMed Web of Science ®Google Scholar
• Mayer R, Kartenbeck J, Büchler M, et al. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol. 1995;131(1):137–150.
   PubMed Web of Science ®Google Scholar
• Schaub TP, Kartenbeck J, König J, et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol. 1999;10(6):1159–1169.
   PubMed Web of Science ®Google Scholar
• Schaub TP, Kartenbeck J, König J, et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol. 1999;10(6):1159–1169.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K-I, et al. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. European J Pharmaceut Sci. 2006;27(5):447–486.
   PubMed Web of Science ®Google Scholar
• Cui Y, König J, Buchholz JK, et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999;55(5):929–937.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996;56(18):4124–4129.
   PubMed Web of Science ®Google Scholar
• Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets. 2011;12(5):631–646.
   PubMed Web of Science ®Google Scholar
• Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537–592.
   PubMed Web of Science ®Google Scholar
• Chu XY, Kato Y, Niinuma K, et al. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther. 1997;281(1):304–314.
   PubMed Web of Science ®Google Scholar
• Keitel V, Kartenbeck J, Nies AT, et al. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology. 2000;32(6):1317–1328.
   PubMed Web of Science ®Google Scholar
• Konig J, Nies AT, Cui Y, et al. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta. 1999;1461(2):377–394.
   PubMed Web of Science ®Google Scholar
• Myint K, Li Y, Paxton J, et al. Multidrug resistance-associated protein 2 (MRP2) mediated transport of oxaliplatin-derived platinum in membrane vesicles. Plos One. 2015;10(7):e0130727.
   Web of Science ®Google Scholar
• Koike K, Kawabe T, Tanaka T, et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997;57(24):5475–5479.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204(3):216–237.
   PubMed Web of Science ®Google Scholar
• Gerk PM, Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther. 2002;302(2):407–415.
   PubMed Web of Science ®Google Scholar
• Matsson P, Pedersen JM, Norinder U, et al. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res. 2009;26(8):1816–1831.
   PubMed Web of Science ®Google Scholar
• Wortelboer HM, Usta M, Van Der Velde AE, et al. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol. 2003;16(12):1642–1651.
   PubMed Web of Science ®Google Scholar
• Kiuchi Y, Suzuki H, Hirohashi T, et al. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998;433(1):149–152.
   PubMed Web of Science ®Google Scholar
• Kool M, De Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997;57(16):3537–3547.
   PubMed Web of Science ®Google Scholar
• Scheffer GL, Kool M, De Haas M, et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab Investigation. 2002;82(2):193–201.
   PubMed Web of Science ®Google Scholar
• König J, Rost D, Cui Y, et al. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology. 1999;29(4):1156–1163.
   PubMed Web of Science ®Google Scholar
• Rost D, König J, Weiss G, et al. Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia. Gastroenterology. 2001;121(5):1203–1208.
   PubMed Web of Science ®Google Scholar
• Kool M, van der Linden M, De Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci. 1999;96(12):6914–6919.
   PubMed Web of Science ®Google Scholar
• Zeng H, Bain LJ, Belinsky MG, et al. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 1999;59(23):5964–5967.
   PubMed Web of Science ®Google Scholar
• Zelcer N, Saeki T, Reid G, et al. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001;276(49):46400–46407.
   PubMed Web of Science ®Google Scholar
• Borst P, Balzarini J, Ono N, et al. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res. 2004;62(1):1–7.
   PubMed Web of Science ®Google Scholar
• Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999;5(9):1048–1051.
   PubMed Web of Science ®Google Scholar
• Robbins BL, Connelly MC, Marshall DR, et al. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl) adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol Pharmacol. 1995;47(2):391–397.
   PubMed Web of Science ®Google Scholar
• Alt FW, Kellems RE, Bertino JR, et al. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem. 1978;253(5):1357–1370.
   PubMed Web of Science ®Google Scholar
• Schimke RT, Kaufman RJ, Alt FW, et al. Gene amplification and drug resistance in cultured murine cells. Science. 1978;202(4372):1051–1055.
   PubMed Web of Science ®Google Scholar
• Schimke RT. Gene amplification, drug resistance, and cancer. Cancer Res. 1984;44(5):1735–1742.
   PubMed Web of Science ®Google Scholar
• Zalatnai A. and Molnar J. Molecular background of chemoresistance in pancreatic cancer. in vivo, 2007;21(2):339–347.
   Google Scholar
• Van Aubel RA, Smeets PHE, Peters JGP, et al. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002;13(3):595–603.
   PubMed Web of Science ®Google Scholar
• Sassi Y, Lipskaia L, Vandecasteele G, et al. Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. J Clin Invest. 2008;118(8):2747–2757.
   PubMed Web of Science ®Google Scholar
• Borst P, De Wolf C, van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflügers Archiv-European J Physiol. 2007;453(5):661–673.
   PubMed Web of Science ®Google Scholar
• Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci. 2003;100(16):9244–9249.
   PubMed Web of Science ®Google Scholar
• Lin ZP, Zhu YL, Johnson DR, et al., Disruption of cAMP and PGE2 transport by Mrp4 deficiency alters cAMP-mediated signaling and nociceptive response. Molecular Pharmacology, 2007;91(5).
   Google Scholar
• Hanaka H, Pawelzik S-C, Johnsen JI, et al. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci. 2009;106(44):18757–18762.
   PubMed Web of Science ®Google Scholar
• Wielinga P, Reid G, Challa EE, et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol. 2002;62(6):1321–1331.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Feng C, Liao W, et al. Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model. Cancer cell int. 2013;13(1):65.
   Google Scholar
• Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003;63(5):1094–1103.
   PubMed Web of Science ®Google Scholar
• Wijnholds J, Mol CAAM, Van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci. 2000;97(13):7476–7481.
   PubMed Web of Science ®Google Scholar
• Dean M. The human auditory brain-stem response to high click rates: aging effects. Am J Audiol. 2002;11:12–12.
   Google Scholar
• Pratt S, Shepard RL, Kandasamy RA, et al. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther. 2005;4(5):855–863.
   PubMed Web of Science ®Google Scholar
• Oguri T, Achiwa H, Sato S, et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther. 2006;5(7):1800–1806.
   PubMed Web of Science ®Google Scholar
• Sho M., Adachi M, Taki T, et al. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. International journal of cancer, 1998. 79(5):509-516.
   Google Scholar
• Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev. 2006;86(3):849–899.
   PubMed Web of Science ®Google Scholar
• Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290(5497):1771–1775.
   PubMed Web of Science ®Google Scholar
• Lee M-H, Lu K, Hazard S, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet. 2001;27(1):79–83.
   PubMed Web of Science ®Google Scholar
• Jani M, Ambrus C, Magnan R, et al. Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics. Arch Toxicol. 2014;88(6):1205–1248.
   PubMed Web of Science ®Google Scholar
• Mao Q, Unadkat JD. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport—an update. Aaps J. 2015;17(1):65–82.
   PubMed Web of Science ®Google Scholar
• König J, Müller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65(3):944–966.
   PubMed Web of Science ®Google Scholar
• Mo W., Liu JY, Zhang J, et al. Biochemistry and pharmacology of human ABCC1/MRP1 and its role in detoxification and in multidrug resistance of cancer chemotherapy. In: Recent advances in cancer research and therapy. Amsterdam, The Netherlands: Elsevier; 2012. p. 371–404.
   Google Scholar
• Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci. 1998;95(26):15665–15670.
   PubMed Web of Science ®Google Scholar
• Lee JS, Scala S, Matsumoto Y, et al. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem. 1997;65(4):513–526.
   PubMed Web of Science ®Google Scholar
• Chen YN, Mickley LA, Schwartz AM, et al. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem. 1990;265(17):10073–10080.
   PubMed Web of Science ®Google Scholar
• Özvegy C, Litman T, Szakács G, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001;285(1):111–117.
   PubMed Web of Science ®Google Scholar
• Sarkadi B, Homolya L, Szakács G, et al. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev. 2006;86(4):1179–1236.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 2004;279(23):24218–24225.
   PubMed Web of Science ®Google Scholar
• Woodward OM, Kottgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci. 2009;106(25):10338–10342.
   PubMed Web of Science ®Google Scholar
• Ding X-W, Wu J-H, Jiang C-P. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sciences. 2010;86(17):631–637.
   PubMed Web of Science ®Google Scholar
• Brózik A, Hegedüs C, Erdei Z, et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol. 2011;7(5):623–642.
   PubMed Web of Science ®Google Scholar
• Cusatis G, Gregorc V, Li J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006;98(23):1739–1742.
   PubMedGoogle Scholar
• Hegedus C, Ozvegy-Laczka C, Szakács G, et al. Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors? Curr Cancer Drug Targets. 2009;9(3):252–272.
   PubMed Web of Science ®Google Scholar
• Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61(8):3458–3464.
   PubMed Web of Science ®Google Scholar
• Scheffer GL, Maliepaard M, Pijnenborg AC, et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone-and topotecan-resistant cell lines. Cancer Res. 2000;60(10):2589–2593.
   PubMed Web of Science ®Google Scholar
• Rocchi E, Khodjakov A, Volk EL, et al. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun. 2000;271(1):42–46.
   PubMed Web of Science ®Google Scholar
• Allen JD, Brinkhuis RF, Wijnholds J, et al. The mouse Bcrp1/Mxr/Abcp gene amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999;59(17):4237–4241.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol. 2011;3(11):153–164.
   PubMed Web of Science ®Google Scholar
• Li D, Xie K, Wolff R, et al. Pancreatic cancer. The Lancet. 2004;363(9414):1049–1057.
   PubMed Web of Science ®Google Scholar
• Reid G, Wielinga P, Zelcer N, et al., Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Molecular Pharmacology, 2003;63(5):1094–1103.
   Google Scholar
• Jordheim LP, Durantel D, Zoulim F, et al. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013;12(6):447–464.
   PubMed Web of Science ®Google Scholar
• Robey RW, Honjo Y, van de Laar A, et al. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochimica Et Biophysica Acta (Bba)-Biomembranes. 2001;1512(2):171–182.
   PubMed Web of Science ®Google Scholar
• Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 2001;61(18):6635–6639.
   PubMed Web of Science ®Google Scholar
• Samalin E, Bouché O, Thézenas S, et al. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre phase I/II trial. Br J Cancer. 2014;110(5):1148–1154.
   PubMed Web of Science ®Google Scholar
• Stacy AE, Jansson PJ, Richardson DR. Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol. 2013;84(5):655–669.
   PubMed Web of Science ®Google Scholar
• Morisaki K, Robey RW, Ozvegy-Laczka C, et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol. 2005;56(2):161–172. .
   PubMed Web of Science ®Google Scholar
• Özvegy C, Váradi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter modulation of substrate specificity by a point mutation. J Biol Chem. 2002;277(50):47980–47990.
   PubMed Web of Science ®Google Scholar
• Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev. 2013;32(1–2):211–227.
   PubMed Web of Science ®Google Scholar
• Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Meta Rev. 2013;32(1–2):211–227.
   PubMed Web of Science ®Google Scholar
• Ueda K. ABC proteins protect the human body and maintain optimal health. Biosci Biotechnol Biochem. 2011;75(3):401–409.
   PubMed Web of Science ®Google Scholar
• Fromm MF. Importance of P-glycoprotein at blood–tissue barriers. Trends Pharmacol Sci. 2004;25(8):423–429.
   PubMed Web of Science ®Google Scholar
• Patel J, Mitra AK. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics. 2001;2(4):401–415.
   PubMedGoogle Scholar
• Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev. 2009;109(7):2989–3011.
   PubMed Web of Science ®Google Scholar
• Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev. 2009;109(7):2989–3011.
   PubMed Web of Science ®Google Scholar
• Roy S, Kenny E, Kennedy S, et al. MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. Anticancer Res. 2007;27(3A):1325–1330.
   PubMed Web of Science ®Google Scholar
• Li J, Li Z-N, Du Y-J, et al. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer. 2009;10(6):414–421.
   PubMed Web of Science ®Google Scholar
• Robey RW, Steadman K, Polgar O, et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 2004;64(4):1242–1246.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Lavi O, Hall MD, et al. Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol. 2016;56:85–102.
   PubMed Web of Science ®Google Scholar
• Yang K, Fu L-W. Mechanisms of resistance to BCR–ABL TKIs and the therapeutic strategies: a review. Crit Rev Oncol Hematol. 2015;93(3):277–292.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;2001(344):1031–1037.
   Web of Science ®Google Scholar
• Galaverna F, Ghiggi C, Guolo F, et al. Management of early stage chronic myeloid leukemia: state-of-the-art approach and future perspectives. Curr Cancer Drug Targets. 2013;13(7):749–754.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129–141.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Van Beijnum JR, Nowak-Sliwinska P, Huijbers EJM, et al. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev. 2015;67(2):441–461.
   PubMed Web of Science ®Google Scholar
• Wu C-P, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1(2):93–105.
   PubMedGoogle Scholar
• Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819–823.
   PubMed Web of Science ®Google Scholar
• Liu T, Li Z, Zhang Q, et al. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance. Oncotarget, 2016;7(50):83502–83513.
   Google Scholar
• Fisher M, Abramov M, Van Aerschot A, et al. Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res. 2007;35(4):1064–1074.
   PubMed Web of Science ®Google Scholar
• Li H, Zhou S, Li T, et al. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference. Hepato-Gastroenterology. 2012;59(119):2238–2242.
   PubMed Web of Science ®Google Scholar
• Perez J, Bardin C, Rigal C, et al. Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. Anticancer Res. 2011;31(9):2813–2820.
   PubMed Web of Science ®Google Scholar
• Wu H, Hait WN, Yang J-M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003;63(7):1515–1519.
   PubMed Web of Science ®Google Scholar
• Eckstein F. The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther. 2007;7(7):1021–1034.
   PubMed Web of Science ®Google Scholar
• Zhang G, Wang Z, Qian F, et al. Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in human gastric cancer. Oncology Reports. 2015;33(3):1147–1154.
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–866.
   PubMed Web of Science ®Google Scholar
• Bao L, Hazari S, Mehra S, et al. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012;180(6):2490–2503.
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 2010;251(6):1056–1063.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu H, Liu X, et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76(5):582–588.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang H, Assaraf YG, et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat. 2016;27:14–29.
   PubMed Web of Science ®Google Scholar
• Abba M.L, Patil N, Leupold JH, et al. MicroRNAs as novel targets and tools in cancer therapy. Cancer letters, 2017;387:84–94.
   Google Scholar
• Bar-Zeev M, Assaraf YG, Livney YD. β-Casein nanovehicles for oral delivery of chemotherapeutic drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells. Oncotarget. 2016.
   PubMed Web of Science ®Google Scholar
• Livney YD, Assaraf YG. Rationally designed nanovehicles to overcome cancer chemoresistance. Adv Drug Deliv Rev. 2013;65(13):1716–1730.
   PubMed Web of Science ®Google Scholar
• Shapira A, Davidson I, Avni N, et al. β-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: stability, target-activated release and cytotoxicity. Eur J Pharmaceutics Biopharmaceutics. 2012;80(2):298–305.
   PubMed Web of Science ®Google Scholar
• Sun T, Zhang YS, Pang B, et al. Engineered nanoparticles for drug delivery in cancer therapy. Angewandte Chemie Int Edit. 2014;53(46):12320–12364.
   PubMed Web of Science ®Google Scholar
• Yang X, Singh A, Choy E, et al. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Scientific reports, 2015;5:8509.
   Google Scholar
• Zhang M, Akbulut M. Adsorption, desorption, and removal of polymeric nanomedicine on and from cellulose surfaces: effect of size. Langmuir. 2011;27(20):12550–12559.
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151.
   PubMed Web of Science ®Google Scholar
• Zhang -T-T, Li W, Meng G, et al. Strategies for transporting nanoparticles across the blood–brain barrier. Biomater Science. 2016;4(2):219–229.
   PubMed Web of Science ®Google Scholar
• Kapse-Mistry S., Govender T, Srivastava R, et al. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 2014;5:159.
   PubMed Web of Science ®Google Scholar
• Li Z, Liu K, Sun P, et al. Poly (D, L-lactide-co-glycolide)/montmorillonite nanoparticles for improved oral delivery of exemestane. J Microencapsul. 2013;30(5):432–440.
   PubMed Web of Science ®Google Scholar
• Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002;4(3):1.
   PubMed Web of Science ®Google Scholar
• Ogawara K-I, Un K, Tanaka K-I, et al. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells. J Control Release. 2009;133(1):4–10.
   PubMed Web of Science ®Google Scholar
• Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. 1997;57(23):5246–5253.
   PubMed Web of Science ®Google Scholar
• Kaye SB. Reversal of drug resistance in ovarian cancer: where do we go from here? J Clin Oncol. 2008;26(16):2616–2618.
   PubMed Web of Science ®Google Scholar
• Shaffer BC, Gillet J-P, Patel C, et al. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat. 2012;15(1–2):62–69.
   PubMed Web of Science ®Google Scholar
• Norman BH, Lander PA, Gruber JM, et al. Cyclohexyl-linked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1). Bioorg Med Chem Lett. 2005;15(24):5526–5530.
   PubMed Web of Science ®Google Scholar
• O’Connor R, O’Leary M, Ballot J, et al. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2007;59(1):79–87.
   PubMed Web of Science ®Google Scholar
• Kondratov RV, Komarov PG, Becker Y, et al. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc Natl Acad Sci. 2001;98(24):14078–14083.
   PubMed Web of Science ®Google Scholar
• Dantzig AH, De Alwis DP, Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev. 2003;55(1):133–150.
   PubMed Web of Science ®Google Scholar
• Li Y, Revalde JL, Reid G, et al. Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metab Rev. 2010;42(4):590–611.
   PubMed Web of Science ®Google Scholar
• Norman BH, Gruber JM, Hollinshead SP, et al. Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1). Bioorg Med Chem Lett. 2002;12(6):883–886.
   PubMed Web of Science ®Google Scholar
• Ahmad J, Akhter S, Khan MA, et al. Engineered nanoparticles against MDR in cancer: the state of the art and its prospective. Curr Pharm Des. 2016;22(28):4360–4373.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2012;31(2):73–99.
   PubMed Web of Science ®Google Scholar
• Zhang Y-K, Wang Y-J, Gupta P, et al. Multidrug resistance proteins (MRPs) and cancer therapy. Aaps J. 2015;17(4):802–812.
   PubMed Web of Science ®Google Scholar